CALCA and bone disorder: The calcitonin (CT), Class B1 GPCRs (CTRs), are highly expressed on osteoclasts and have been exploited therapeutically for treatment of bone disorders, including Paget’s disease, hypercalcemia of malignancy and osteoporosis [2], [3], [4], [5].